Absci Corp (ABSI)’s ownership amendment reports that BlackRock, Inc. beneficially owned 13,396,310 common shares, equal to 7.8% of the class. BlackRock reported sole voting power over 13,106,779 shares and sole dispositive power over 13,396,310 shares, with no shared voting or dispositive power.
BlackRock says the reported amount reflects securities beneficially owned or deemed beneficially owned by certain business units and subsidiaries and affiliates, excluding other business units whose ownership is disaggregated. It also states that various persons may receive dividends or sale proceeds, but no one person’s interest exceeds 5% of Absci’s outstanding common shares.
Absci Corp (ABSI) Chief Executive Officer and director Sean McClain had 23,293 common shares withheld by the issuer on October 12, 2026. The shares covered a tax withholding obligation connected with restricted stock unit vesting; the transaction was not a discretionary trade. McClain's reported direct common-stock holdings following the transaction were 8,632,262 shares. The transaction row reports a price of $10.16 per share.
Todd Bedrick, Absci Corp (ABSI)’s SVP, CAO, had 22,325 common shares withheld by the issuer on October 12, 2026, to cover tax withholding tied to restricted stock unit vesting. The footnote says this was not a discretionary trade. The reported price per share was $10.16. Bedrick’s direct common-stock holding afterward was 199,128 shares, including 2,264 shares acquired March 31, 2026 and 2,247 acquired September 30, 2026 under the 2021 Employee Stock Purchase Plan.
Absci Corp CFO / CBO Zachariah Jonasson had 387 common shares withheld at $10.16 per share on October 12, 2026, to cover the tax withholding obligation tied to vesting restricted stock units. The footnote states this was not a discretionary trade. He reported 484,918 shares held directly afterward, including 2,161 shares acquired through the Absci Corporation 2021 Employee Stock Purchase Plan on September 30, 2026.
Absci Corp (ABSI) reported that officer Zachariah Jonasson, CFO / CBO, had 8,320 shares of common stock withheld on 2026-08-31 to cover a tax withholding obligation related to the vesting of restricted stock units. This was a non-discretionary tax-withholding disposition, and Jonasson now directly holds 483,144 common shares.
Absci Corporation reported continued operating losses while advancing its AI-driven biologics pipeline in the quarter ended June 30, 2026. Partner program revenue declined to $0.3 million for the quarter and $0.5 million for the first half of 2026, down sharply from 2025 due to milestone timing and program mix. Net loss widened to $33.2 million for the quarter and $62.8 million year-to-date, driven mainly by higher research and development spending as lead antibody ABS-201 progresses through clinical development.
Absci strengthened its balance sheet with a June 2026 public equity offering that raised approximately $93.6 million net and additional at-the-market sales, bringing cash, cash equivalents and marketable securities to $201.1 million as of June 30, 2026. Management believes this provides funding for at least 12 months. The company highlighted its AI-native Integrated Drug Creation platform and early clinical progress of ABS-201, including positive interim Phase 1 safety data and a long estimated half-life supporting infrequent dosing, while emphasizing that it remains in early stages with no milestone or royalty revenue yet realized.
Absci Corporation reported second-quarter 2026 results and pipeline updates. Revenue from partner programs was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier. Research and development expenses rose to $22.6 million from $20.5 million, and selling, general, and administrative expenses increased to $9.2 million from $8.5 million. Net loss widened to $33.2 million from $30.6 million.
Cash, cash equivalents, and marketable securities were $201.1 million as of June 30, 2026, up from $125.7 million as of March 31, 2026, reflecting $93.6 million of net proceeds from a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company. Absci now believes this cash position will fund operating plans into the second half of 2028.
Absci highlighted positive interim Phase 1 data from the HEADLINE trial of ABS-201 for pattern hair loss, with blinded data suggesting the drug was well tolerated and an estimated half-life of at least 65 days, supporting potential dosing two or three times over six months. The company anticipates interim proof-of-concept data for pattern hair loss in the second half of 2026, full proof-of-concept data in early 2027, and initiation of a Phase 2 trial of ABS-201 for endometriosis in the fourth quarter of 2026.
Absci Corp reported that its CMO and Head of R&D, Ransi Mudalinayake, received two grants of employee stock options. One grant covers 383,000 options with a $7.93 exercise price expiring on August 2, 2036, and another covers 650,000 options at $2.57 expiring on March 2, 2036. For each grant, 25% of the shares vest on the first anniversary of the grant date, with the remaining shares vesting in 36 approximately equal monthly installments, subject to continued service.
Absci Corp filed an initial statement of beneficial ownership for officer Somaratne Ransi Mudalinayake, who serves as CMO and Head of R&D. The report lists no transactions and shows no Absci securities reported as beneficially owned, establishing a baseline ownership position for this new reporting person.
Absci Corp director Mary T. Szela made an open-market purchase of 12,900 shares of Common Stock at $11.54 per share on June 30, 2026. After this transaction, she directly owns 21,300 shares. The trade was executed in accordance with the issuer's trading policies.